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Abstract
Pancreatic tumors are usually diagnosed at an advanced stage in the progression of the disease, thus reducing the survival
chances of the patients. Non-invasive early detection would greatly enhance therapy and survival rates. Toward this aim, we
investigated in a pilot study the power of methylation changes in whole blood as predictive markers for the detection of
pancreatic tumors. We investigated methylation levels at selected CpG sites in the CpG rich regions at the promoter regions
of p16, RARbeta, TNFRSF10C, APC, ACIN1, DAPK1, 3OST2, BCL2 and CD44 in the blood of 30 pancreatic tumor patients and
in the blood of 49 matching controls. In addition, we studied LINE-1 and Alu repeats using degenerate amplification
approach as a surrogate marker for genome-wide methylation. The site-specific methylation measurements at selected CpG
sites were done by the SIRPH method. Our results show that in the patient’s blood, tumor suppressor genes were slightly
but significantly higher methylated at several CpG sites, while repeats were slightly less methylated compared to control
blood. This was found to be significantly associated with higher risk for pancreatic ductal adenocarcinoma. Additionally,
high methylation levels at TNFRSCF10C were associated with positive perineural spread of tumor cells, while higher
methylation levels of TNFRSF10C and ACIN1 were significantly associated with shorter survival. This pilot study shows that
methylation changes in blood could provide a promising method for early detection of pancreatic tumors. However, larger
studies must be carried out to explore the clinical usefulness of a whole blood methylation based test for non-invasive early
detection of pancreatic tumors.
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Introduction
Pancreatic cancer is the fourth most common cause of cancer-
related mortality worldwide, with the majority of cases leading to
death within a relatively short time [1]. Pancreatic cancer is
associated with no or minimal symptoms making detection of this
potentially curable malignancy difficult to achieve. Hence, the late
onset of symptoms and delayed diagnosis of the disease severely
limits survival in these patients. Currently, the overall five year
survival rate following pancreaticoduodenectomy for pancreatic
cancer is as low as 15–20% [2]. An early, reliable, and noninvasive
test with the potential to increase the rates of detection and to
provide early warning for the presence of the malignancy is
urgently required. Such a test would increase the rate of survival
and the cure rate. However, knowledge on the molecular
pathogenesis of pancreatic cancer and availability of possible
biomarkers with clinical value to be used for the development of
such a test are limited.
Most investigations of biomarkers in patients with cancers have
focused on the assessment of differences in methylation levels
between tumor and histologically normal tissue. Indeed, aberrant
DNA methylation has been found to play an important role in the
development, progression and outcome of most cancers [3]. Two
forms of frequently observed methylation changes in cancer take
place: global hypomethylation that is largely observed in gene-
poor regions and repetitive DNA and gene-specific hypermethyla-
tion of CpG islands [4]. Hypermethylation of promoter regions
has been frequently described in pancreatic [5–8] and other
cancers [9–11].
However, since most studies are focusing on methylation
changes in the tumor tissue itself, in such cases, access to the
diseased tissue by surgery is required, which limits its clinical utility
as non-invasive early diagnosis. Alternatively, body fluids such as
saliva [12], sputum [13], bronchoalveolar lavage [14], urine [15]
and stools [16] that are in contact with tumors are potential
sources of cancer cell DNA for analysis of epigenetic changes.
Another readily available biological sample that can be obtained
noninvasively is peripheral blood. It is well known that DNA
fragments are frequently abundant in sera/plasma of cancer
patients (about 200 ng/ml) [17] with significantly higher levels in
patients with metastasis [18]. A number of studies have evaluated
the potential of circulating tumor-related DNA in serum for
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molecular diagnosis and prognosis of various types of cancer
[19,20].
Also, most importantly, there is growing evidence that
methylation changes arise systematically and may be measured
in surrogate tissue, such as peripheral blood leukocytes. Most of
the studies on quantitative methylation in whole blood to
differentiate tumors patients from healthy controls have used
global methylation assays targeting repetitive elements (like Alu
and LINE1), while only a few have investigated specific loci. In
pancreatic tumor patients, only one previous report has been
published investigating the power of DNA methylation changes in
leukocytes to discriminate pancreatic cancer patients from healthy
controls [21]. The authors could identify five sites (IL10, LCN2,
ZAP70, AIM2, TAL1) that identify pancreatic cancer patients
from controls. However, they did not study repetitive elements and
did not correlate the methylation values to the clinical parameters
or to the progression of the disease.
The aim of the present pilot study was to use a highly sensitive
quantitative method to determine whether a difference exists
between selected tumor suppressor genes (p16, RARbeta,
TNFRSF10C, APC, ACIN1, DAPK1, 3OST2, BCL2 and
CD44) and genome-wide repetitive sequence (LINE-1 and Alu)
methylation in peripheral blood of subjects with pancreatic cancer
and healthy controls. Moreover, we correlated the methylation
values with clinical-morphological variables and determined the
influence on survival rates. Additionally, we examined the
methylation level in corresponding malignant tissue samples.
Our pilot study shows that DNA methylation changes in whole
blood could indeed be associated with the presence of pancreatic
tumors and with the progression of the disease.
Results
Peripheral Blood Derived DNA Methylation Analysis
In this pilot study, we investigated locus specific methylation at
selected CpGs at Alu and LINE-1 repeats and at promoter regions
of nine tumor suppressor genes. Using the SIRPH protocol
(SNuPE combined with ion pair reverse phase HPLC) [22,23] we
measured methylation at three CpG sites, in the Alu consensus
sequence, while two CpG sites were analyzed at LINE-1 repeats.
At tumor suppressor genes we measured one CpG site in the p16,
BCL2, DAPK1, TNFRSF10C, CD44 promoter regions, while two
CpG sites were measured in the APC, 3OST2, ACIN1 and
RARbeta promoter regions. Methylation levels at selected CpG
sites were quantitatively evaluated by bisulfite treatment of the
DNA and subsequent quantification of methylation at selected
specific CpG sites by the SIRPH protocol. Details of the studied
regions are shown in Figure S1. Blood samples for DNA extraction
were available from 26 subjects of the 30 pancreatic cancer cases.
The clinical characteristics of the patients included in this study
are summarized in Table 1. Controls used in this study were
matching for age and gender distribution.
The average methylation levels at each CpG site for blood
derived DNA from cancer patients and controls are summarized
in Table 2 and Figure 1. We could observe two trends. First, at
Alu and LINE-1 repeats, mean methylation level in patients was
slightly lower than mean methylation level in controls. Second, at
tumor suppressor genes mean methylation level was higher in
patients than in controls, with the exception of APC SN2
(Figure 1). Methylation level difference was highly significant
(p,0.0001) for all CpGs in LINE-1, Alu repeats and in p16,
APC SN1, ACIN1 SN1 and SN3, BCL2, CD44, TNFRSF10C.
Peripheral Blood Relative Methylation Association with
Presence of Pancreatic Ductal Adenocarcinoma
After observing significant differences in blood methylation
between patients and healthy controls, we performed logistic
regression analysis to examine the association between relative
methylation levels at each of the investigated regions (gene
promoter regions and repetitive elements) and pancreatic ductal
adenocarcinoma presence in patients (Table 3). In this model,
methylation was categorized into three groups divided at the 33rd
and 66th percentiles, with the highest tertile of relative methylation
serving as reference for Alu and LINE-1. The lowest tertile served
as reference for promoters of tumor suppressor genes p16, APC,
30ST2, DAPK1, ACIN1, BCL2, CD44, RARbeta,
TNFRSCF10C. We observed that in patients with lowest tertile
of LINE-1 SN1 (OR 10.4, 95%CI 2.3-47.7) and LINE-1 SN8 (OR
7.8, 95%CI 1.9-32.2), relative methylation had a significantly
higher prevalence of pancreatic cancer. Similar findings were
observed in the lowest tertile of Alu SN1 (OR 8.2, 95%CI 1.9-
35.6), Alu SN3 (OR 7.4, 95%CI 1.9-29.4) and Alu SN4 (OR 7.7,
95%CI 1.8-32.3) (Table 3).
The highest relative methylation tertile of seven tumor
suppressor gene promoter regions also showed an association
with the increased prevalence of pancreatic cancer. Single
investigated CpG of p16 (OR 10.4, 95%CI 2.0-54.7), BCL2
(OR 33.8, 95%CI 3.6-314.3), CD44 (OR 10.3, 95%CI 2.0-52.3)
and TNFRSF10C (OR 11.8, 95%CI 2.2-64.1) were associated
with pancreatic cancer. However, DAPK1 (OR 1.6, 95%CI 0.6-
4.6) does not affect the risk, as methylation levels were not
significantly different between patients and controls. In contrast to
repetitive elements where all studied CpGs showed the same
significant results, when we analyzed more than one CpG in the
Table 1. Clinical characteristics of patients included in this
study.
Characteristic Cases (%)
Control
(%)
Age (years) ,65 12 (40.0) 30 (61.2)
$65 18 (60.0) 19 (38.8)
Gender female 16 (53.3) 30 (61.2)
male 14 (46.7) 19 (38.8)
Stage (UICC classification) I/II 8 (26.6)
III/IV 22 (72.4)
T stage (TNM classification) T1/T2 3 (10.0)
T3/T4 27 (90.0)
Lymph node involvement negative 7 (23.3)
positive 23 (76.7)
Invasion into blood vessels negative 14 (46.7)
positive 16 (53.3)
Invasion into lymph vessels negative 7 (23.3)
positive 23 (76.7)
Perineural spread negative 8 (26.7)
positive 22 (73.3)
Cell differentiation grade G1/G2 4 (13.3)
G3/G4 20 (66.7)
Invasion into peripancreatic tissue negative 8 (26.7)
positive 22 (73.3)
doi:10.1371/journal.pone.0037509.t001
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tumor suppressor gene promoter region only one of the two CpGs
reached a significant increase of relative risk in the highest tertile.
This is true at APC SN1 (OR 3.7, 95% CI 1.1-12.8), ACIN1 SN1
(OR 4.2, 95% CI 1.2-14.8) and RARbeta SN2 (OR 12.1, 95% CI
1.4-106.4) promoter regions. These findings possibly indicate that
not all CpG sites are equal in cancer risk prediction and larger
number of CpGs covering larger areas of the CpG island must be
analyzed to provide higher predictive values. As the methylation
levels at the 3OST2 locus did not differ between cancer patients
and controls no higher prevalence was linked to this locus.
Association of Peripheral Blood Methylation with Clinical-
morphological Features and Survival
Next, we searched for relationships between clinical-morpho-
logical features (Table 1) and Alu, LINE-1 hypomethylation or
hypermethylation of the studied CpG loci of tumor suppressor
genes. For this analysis, we grouped the highest and the middle
tertiles for repetitive elements and the lowest and the middle tertile
for CpG island loci into one variable. Further analysis was
performed using 262 contingency tables (data not shown). Only
high level of TNFRSF10C SN1 methylation was significantly
associated with a positive perineural spread of cancer cells (OR
0.088, 95%CI 0.011-0.717).
Further possible association of site-specific hypermethylation (at
individual CpG sites) with cancer specific overall survival was
evaluated using the Kaplan-Meier method and log-rank test.
Hypomethylation of LINE-1 and Alu were not included in survival
analysis as most of the samples (24/26) were in the lowest tertile. In
this case, association of their hypomethylation with pancreatic
cancer risk is already obvious. Median of the overall survival in
pancreatic ductal adenocarcinoma patients was 13 months (95%
CI 9.4-16.6). Association between hypermethylation of CpGs of
promoters of tumor suppressor genes and cancer specific survival
was evident only at two CpGs, namely TNFRSF10C SN1 and
ACIN1 SN1. Regarding survival, the highest tertile of methylation
of TNFRSF10C SN1 was significantly associated with shorter
survival compared to the middle and the lowest tertile group
(median survival 13 months vs. 22 months, log rank= 0.023)
(Figure 2A). The highest tertile of methylation of ACIN1 SN1 was
also significantly associated with shorter survival compared to the
middle and the lowest tertile group (13 months vs. 17 months, log
rank = 0.012) (Figure 2A).
Comparison of Peripheral Blood and Cancer Tissue DNA
Methylation
Mean methylation levels in peripheral blood were compared to
corresponding pancreatic ductal adenocarcinoma tissues. Methyl-
ation levels of all investigated CpGs for Alu and LINE-1 were
lower in cancer tissues compared to peripheral blood of cancer
patients. Three groups of different methylation patterns could be
distinguished in tissues. The first group of genes displayed higher
methylation levels in cancer tissues than in total blood DNA (p16,
APC, 3OST2, DAPK1). In the second group, methylation levels
were approximately equal (BCL2, CD44, RARbeta,
TNFRSF10C), while in the third group, methylation levels were
lower (ACIN1). However, because of the lack of healthy ductal
pancreatic tissue as control we cannot assess whether methylation
levels in tumor tissue are specific for carcinoma or whether they
merely reflect a tissue-specific variation between blood and
pancreas.
Inter-loci Correlation
Next, we investigated the interaction between different loci in
terms of DNA methylation changes, i.e. inter loci correlations. For
this purpose, we calculated the correlation of methylation between
all loci pair wise and in all three studied tissue samples (blood
samples from control group and from cancer patients).
We examined whether a correlation exists between hyper-
methylation levels of tumor suppressor genes and hypomethylation
levels of repetitive elements in peripheral blood of pancreatic
cancer patients. Using methylation levels as a continuous variable
we found significant associations between methylation levels of
different CpGs at promoter regions and repetitive elements
(Figure 3). We could distinguish negative as well as positive
correlations with the methylation levels of repeats. At least one
CpG in each of p16, APC and 3OST2 showed negative
correlation with methylation levels in CpG at Alu or LINE-1,
while methylation levels in at least one CpG in each of DAPK1,
ACIN1, BCL2, CD44, RARbeta and TNFRSF10C were posi-
tively correlated with methylation levels of one CpG site in the
repeats. Likewise, inter-loci correlations between the non-repeti-
tive loci showed both positive and negative correlations, with
negative correlations between p16 and APC on the one hand, and
ACIN1, CD44, RARbeta and TNFRSF10C on the other hand.
Within the repeats themselves only positive correlations were
observed.
Figure 1. Distribution of various CpGs relative methylation levels in peripheral blood. Boxes extend from 25th to 75th percentiles and are
divided by a solid line representing the median of each group. Whiskers extend from 5th to 95th percentiles. Each outlier is denoted by a dot.
doi:10.1371/journal.pone.0037509.g001
Table 2. Peripheral blood derived DNA mean methylation
comparison in cases and controls (Mann-Whitney test).
Control Cases
Primer Mean SD Mean SD P values
LINE-1 SN-1 51.99 0.70 50.50 1.32 .0000
SN-8 61.65 0.98 60.38 1.21 .0000
Alu SN-1 30.02 2.57 27.52 0.93 .0000
SN-3 34.53 1.41 32.21 0.95 .0000
SN-4 36.95 1.30 35.65 0.73 .0000
P16 SN-2 24.24 5.66 33.92 14.58 .0000
APC SN-1 5.35 0.96 7.91 4.88 .0007
SN-2 7.47 1.39 6.86 0.93 .0228
30ST2 SN-1 10.96 2.86 12.24 3.08 .0513
SN-2 21.00 6.30 20.75 5.69 .8586
DAPK1 SN-3 11.93 3.01 15.38 6.96 .0584
ACIN1 SN-1 8.85 0.50 12.44 3.72 .0000
SN-3 16.39 2.68 17.19 1.64 .0127
BCL2 SN-1 3.66 1.45 5.30 .83 .0000
CD44 SN-2 3.33 0.41 3.99 1.39 .0000
RARBeta SN-1 7.59 4.49 8.14 1.77 .8760
SN-2 5.38 4.09 7.28 1.61 .0688
TNFRSF10C SN-1 4.92 3.59 5.39 1.50 .0000
SD- standard deviation.
doi:10.1371/journal.pone.0037509.t002
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Table 3. Blood-derived DNA relative methylation is associated with the presence of pancreatic ductal adenocarcinoma in patients.
Gene loci Site
Relative methylation
levels (tertiles in
controls) Controls (%)
Pancreatic adenocarcinoma
patients (%) Adjusted OR* (95% CI)
LINE-1 SN1 High 16 (32.7) 1 (3.3) 1.0 (reference)
Middle 17 (34.7) 1 (3.3) 0.3 (0.3–3.1)
Low 16 (32.7) 24 (80) 10.4 (2.3–47.7)
SN8 High 14 (28.6) 3 (10) 1.0 (reference)
Middle 18 (36.7) 2 (6.7) 0.5(0.1–3.5)
Low 16 (32.7) 21 (70) 7.8(1.9–32.2)
Alu SN1 High 16 (32.7) 0 (0) 1.0 (reference)
Middle 17 (34.7) 5 (16.7) 1.8(0.4–9.3)
Low 16 (32.7) 21 (70) 8.2(1.9–35.6)
SN3 High 16 (32.7) 0 (0) 1.0 (reference)
Middle 17 (34.7) 2 (6.7) 0.6(0.1–4.3)
Low 16 (32.7) 24 (80) 7.4(1.9–29.4)
SN4 High 16 (32.7) 0 (0) 1.0 (reference)
Middle 17 (34.7) 5 (16.7) 1.7(0.3–8.1)
Low 16 (32.7) 21 (70) 7.7(1.8–32.3)
P16 SN-2 Low 16 (32.7) 2 (6.7) 1.0 (reference)
Middle 17 (34.7) 3 (10.0) 1.0(0.1–7.4)
High 16 (32.7) 21 (70.0) 10.4(2.0–54.7)
APC SN-1 Low 16 (32.7) 5 (16.7) 1.0 (reference)
Middle 17 (34.7) 4 (13.3) 0.9(0.2–4.0)
High 16 (32.7) 17 (56.7) 3.7(1.1–12.8)
SN-2 Low 15 (30.6) 14 (46.7) 1.0 (reference)
Middle 17 (34.7) 5 (16.7) 4.4(1.0–19.0)
High 16 (32.7) 3 (10.0) 1.5(0.3–7.3)
30st2 SN-1 Low 16 (32.7) 5 (16.7) 1.0 (reference)
Middle 17 (34.7) 6 (20.0) 0.8(0.2–2.7)
High 16 (32.7) 15 (50.0) 2.1(0.7–6.8)
SN-2 Low 16 (32.7) 10 (33.3) 1.0 (reference)
Middle 17 (34.7) 5 (16.7) 0.4(0.1–1.3)
High 16 (32.7) 11 (36.7) 0.9(0.3–2.6)
DAPK-1 SN-3 Low 16 (32.7) 7 (23.3) 1.0 (reference)
Middle 17 (34.7) 4 (13.3) 0.4(0.1–1.5)
High 16 (32.7) 15 (50.0) 1.6(0.6–4.6)
ACIN1 SN-1 Low 16 (32.7) 3 (10.0) 1.0 (reference)
Middle 16 (32.7) 3 (10.0) 0.6(0.1–2.7)
High 16 (32.7) 20 (66.7) 4.2(1.2–14.8)
SN-3 Low 16 (32.7) 4 (13.3) 1.0 (reference)
Middle 17 (34.7) 8 (26.7) 1.4(0.4–4.9)
High 16 (32.7) 14 (46.7) 2.6(0.7–9.1)
BCL2 SN-1 Low 14 (28.6) 1 (3.3) 1.0 (reference)
Middle 15 (30.6) 1 (3.3) 1.1(0.1–20.8)
High 14 (28.6) 24 (80.0) 33.8(3.6–314.3)
CD44 SN-2 Low 16 (32.7) 2 (6.7) 1.0 (reference)
Middle 17 (34.7) 4 (13.3) 2.1(0.3–13.2)
High 16 (32.7) 20 (66.7) 10.3(2.0–52.3)
RARBeta SN-1 Low 16 (32.7) 12 (40.0) 1.0 (reference)
Middle 17 (34.7) 4 (13.3) 0.3(0.1–1.0)
High 16 (32.7) 10 (33.3) 0.7(0.3–2.0)
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In the blood of healthy controls, the inter-loci correlations as
seen in the blood of cancer patients were largely maintained.
However, the number of significant inter-loci correlations were
mostly reduced (63 correlations in the blood of pancreatic cancer
patients vs. only 29 correlations in the blood of healthy controls;
Figure 3). This could be due to two reasons: 1) Lower variability of
methylation levels in healthy controls compared to those found in
the blood of cancer patients, which would result in less significant
correlations. 2) Higher variability of methylation observed in
tumor blood possibly caused by the presence of the tumor
condition in the patients. This could reflect an organized body
response against the challenge imposed on the body by the
presence of tumor growth. What is of particular interest is the
opposite direction of several correlations in the blood of healthy
controls and the blood of cancer patients. Thus, correlations
between APC SN1 and Alu SN3 and LINE-1 SN1 are positive in
the blood of healthy controls, but negative in the blood of cancer
patients. Moreover, correlations between TNFRSF10C SN1 and
Alu SN1, 2 and 3 are negative in the blood of healthy controls but
positive in the blood samples of cancer patients.
Correlation between Methylation in Peripheral Blood and
Malignant Tissues of Pancreatic Ductal Adenocarcinoma
Patients
The correlation between paired tumor and peripheral blood
samples was estimated for each marker (Figure 4). In this context,
three groups of correlations must be discussed: 1) correlation
between the same loci in blood and in pancreatic tumor tissue, 2)
reciprocal correlations, i.e. correlation between two loci with a
correlation between blood and pancreatic tissue and between
pancreatic tissue and blood, and 3) all other correlations. In the
first category, we could find only one instance of ‘self’ correlating
loci as methylation of ACIN1 SN1 exhibited a strong positive
correlation between pancreatic cancer tissues and peripheral blood
(r = 0.788, p,0.001). In the second category, we could distinguish
two such correlations; first ACIN1 SN1 in blood correlated with
p16 SN2 in pancreatic tumor tissue (r=20.528, p = 0.006) and,
reciprocally, p16 SN2 in blood correlated with ACIN1 SN1 in
pancreatic tumor tissue (r=20.519, p = 0.007). The second
correlation in this category was found between RARB SN1 in
blood and ACIN1 SN1 (r=0.536, p = 0.005) and SN3 (r=0.504,
p = 0.009) in pancreatic tumor tissue and, reciprocally, ACIN1
SN1 (r=20.664, p,0.001) and SN3 (r=20.433, p = 0.027) in
blood correlated with RARbeta SN1 in pancreatic tumor tissue.
Several correlations were observed in the third category.
TNFRSF10C SN1 methylation in peripheral blood was well
correlated with the methylation levels of LINE-1, Alu, p16,
Table 3. Cont.
Gene loci Site
Relative methylation
levels (tertiles in
controls) Controls (%)
Pancreatic adenocarcinoma
patients (%) Adjusted OR* (95% CI)
SN-2 Low 16 (32.7) 1 (3.3) 1.0 (reference)
Middle 16 (32.7) 12 (40.0) 12.1(1.4–106.4)
High 16 (32.7) 13 (43.3) 14.2(1.6–125.1)
TNFRSF10C SN-1 Low 16 (32.7) 2 (6.7) 1.0 (reference)
Middle 16 (32.7) 5 (16.7) 2.3(0.4–14.4)
High 16 (32.7) 19 (63.3) 11.8(2.2–64.1)
*Model is adjusted for age groups (,65 years and.= 65 years).
doi:10.1371/journal.pone.0037509.t003
Figure 2. Kaplan-Meier survival estimates of overall survival
for methylation levels in peripheral blood of cancer patients.
ACIN1 SN1 (A), log rank=0.012 and TNFRSF10C SN1 (B), log-
rank=0.023.
doi:10.1371/journal.pone.0037509.g002
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ACIN1 and RARbeta in pancreatic cancer tissue. Spearman’s
negative correlation value ranged from 20.421 to 20.392 (p value
0.032–0.048), while the positive correlation value ranged from
0.423 to 0.56 (p value 0.005–0.048). At ACIN1 SN1, methylation
levels in cancer tissues correlated well with methylation levels of
LINE-1, Alu, p16 (see above), APC, BCL2, RARbeta and
TNFRSF10C in peripheral blood. Spearman’s negative correla-
tion value ranged from 20.519 to 20.455 (p value 0.007–0.02),
while the positive correlation value ranged from 0.449 to 0.634 (p
value 0.001–0.021). Moreover, RARbeta in blood correlated with
TNFRSF10C, CD44, ACIN1, APC, p16 and LINE-1 in
pancreatic tumor tissue. The negative correlation value ranged
from 20.72 to 20.398 (p value,0.001–0.044), while the positive
correlation value ranged from 0.44 to 0.47 (p value 0.015–0.038).
These correlations are of great interest since TNFRSF10C SN1 as
well as ACIN SN1 high methylation levels in peripheral blood
were associated with poor survival.
Discussion
Pancreatic tumors are often diagnosed in advanced stages of the
disease when it has become too late for surgery to cure the disease.
Figure 3. Heatmap showing p values (lower left triangle) and significant Spearman correlation coefficient (r: upper right triangle)
between methylation levels at different CpGs in peripheral blood of pancreatic cancer patients (A) and control group (B) (p values
of .0.05 are in white, the shown r-values are corresponding to p values ,0.05).
doi:10.1371/journal.pone.0037509.g003
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Therefore, one of the ultimate aims in clinical research is to
develop a non-invasive early diagnostic test that would greatly
enhance therapy and survival rates. To this end, we analyzed, in a
pilot study, methylation status changes in the peripheral blood of
pancreatic cancer patients and healthy controls. We observed
lower levels of global methylation as measured by LINE-1 and Alu
Figure 4. Heatmap showing p values and significant Spearman correlation coefficient (r) between methylation levels of different
CpGs in paired peripheral blood and ductal adenocarcinoma tissues (p values of .0.05 are in white, the shown r-values are
corresponding to p values ,0.05).
doi:10.1371/journal.pone.0037509.g004
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repetitive elements and higher methylation levels at promoters of
tumor suppressor genes in the blood of pancreatic cancer patients
compared to the blood of healthy controls. This was clearly
associated with an increased risk for pancreatic cancer.
In the present pilot study, we found significant differences
between cancer cases and controls, with p values for all of the five
LINE-1 and Alu CpGs,0.0001. The methylation of Alu and
LINE-1 repeats using degenerative amplification approaches was
also previously shown to correlate with the 5-methylcytosine
content in the human genome indicating that analysis of Alu and
LINE-1 methylation may serve as a surrogate measure of genomic
methylation levels [24]. Moreover, genomic DNA hypomethyla-
tion status in total blood DNA has recently been associated with
higher risk for developing several cancers, such as colorectal, head
and neck, bladder and breast cancers [25–28]. Therefore,
hypomethylation of LINE-1 and Alu repeats from total blood
could possibly correlate with the presence of inner organ tumors.
This was found to be the case for LINE-1 in several studies [29–
33], while other studies found no differences between cancer cases
and controls [25,34].
The association between methylation in the investigated genes
in peripheral blood of pancreatic ductal adenocarcinoma and
clinical-pathologic parameters in patients is important for the
understanding of the pathogenesis of the disease. According to our
results, methylation levels (or variations) of most of these genes and
repetitive elements in peripheral blood had no significant
correlation to clinical-pathologic parameters of patients. We did
not find any association between global methylation levels (LINE-
1 and Alu methylation) and tumor characteristics. This is
consistent with other findings in colorectal adenoma and bladder
cancer patients [27,28]. However, higher methylation levels at
TNFRSF10C promoter region in peripheral blood was positively
associated with perineural tumor spread.
All of the above-described results demonstrate that levels of
methylation at certain gene promoters in non-cancerous tissues
(such as the studied blood) may be associated with survival in
pancreatic ductal adenocarcinoma patients. We found that
patients with high methylation levels of TNFRSF10C in periph-
eral blood DNA had shorter survival. Although it remains unclear
whether TNFRSF10C plays a pro-apoptotic or an anti-apoptotic
role in tumors, hypermethylation of TNFRSF10C has been
reported in various human cancers [35]. One of the proposed
mechanisms suggests a pro-apoptotic pathway, whereby the
cancer cells gain advantage for proliferation and progression by
inactivating TNFRSF10C through deletion or methylation of the
promoter region [36,37]. Our data are partly compatible with the
latter of the proposed mechanisms since hypermethylation of
TNFRSF10C in peripheral blood of pancreatic ductal adenocar-
cinoma patients is found to be associated with poor survival rates.
Yet, the mechanism of TNFRSF10C downregulation, which is
linked to the development of carcinogenic tissue, is not of direct
relevance here as hypermethylation was observed in the blood
surrogate tissue and not the tumor tissue itself. However,
TNFRSF10C methylation in the blood of cancer patients
positively correlated with LINE-1, Alu and ACIN1 and negatively
with p16 and RARbeta in pancreatic tumor tissue (Figure 3). It is
unlikely that higher methylation of LINE-1 or Alu or lower
methylation of p16 and RARbeta in the cancer tissue itself are
associated with tumor developments. Therefore, we postulate that
hypermethylation of TNFRSF10C in blood exerts its effect on
poor survival rates through its positive correlation with ACIN1
(SN1) tissue methylation, as the latter was also found to strongly
correlate with methylation of blood ACIN1 (SN1) (Figure 3). We
found high methylation levels at ACIN1 in peripheral blood DNA
to be related to poor prognosis. Hypermethylation of the ACIN1
was also found in non-tumorous regions of early stage lung
adenocarcinoma cases and this could be one of the early events in
cancer development [38].
Methylation levels of the gene promoter regions differ between
cancer DNA and peripheral blood DNA. We indentified three
patterns of methylation in cancer tissues. Contrary to our
expectations, some gene promoter regions in cancer tissues
showed equal or lower methylation levels than those in blood
DNA. Moreover, correlation between repetitive DNA sequences
in some genes was negative, while in others, it was positive
(Figure 3). These findings suggest that CpG island methylation
gene promoter region and repetitive sequences are governed by
different mechanisms and selective pressures of tumor progression,
and that these two processes are possibly independent [39]. In a
comprehensive study of satellite DNA hypomethylation, global
DNA hypomethylation and hypermethylation of 55 gene loci in
three types of ovarian epithelial tumors of different malignant
potential and a variety of normal somatic tissues, it was found that
DNA hypomethylation and hypermethylation usually co-exist in
the same tumor but in different sequences [40]. The degree of
gene hypermethylation was associated with the degree of
malignancy of ovarian epithelial tumors. However, this association
was independent of global DNA hypomethylation with the degree
of malignancy. These results were consistent in hepatocellular
carcinoma patients [41]. Clearly, these data show that some inter-
relationship other than a mutual dependency exists between
hypermethylation and hypomethylation of DNA. They possibly
share some pathways in the poorly understood development
resulting in these epigenetic changes. Also, different types of
cancer-linked epigenetic abnormalities can interact in various ways
[42]. Admittedly, conflicting data on dependence between global
hypomethylation and targeted gene hypermethylation may be due
to different methodologies and different CpG sites investigated in
different studies.
Although this pilot study indicates a strong trend for a possible
use of whole blood DNA methylation as marker for presence of
pancreatic adenocarcinoma and its association with the progres-
sion of the disease, special care should be taken before such an
approach is transferred to a clinical setup for the following reasons:
1) The relatively small patient sample size included in this pilot
study; larger studies are needed to confirm informative markers in
a majority of patients. 2) Lack of confirmation using an
independent technology and a second independent set of patients.
3) Lack of verification of the markers specificity (i.e.: are the
observed methylation changes specific for pancreatic adenocarci-
noma) as the observed methylation changes could result from a
general immune response to any tumor or any challenge/stress
imposed on normal physiological conditions. Therefore, our data
must be interpreted with care and over-interpretation must be
avoided. Since this study is a pilot study, it does not provide ‘ready
to use’ clinical markers (albeit clear trends) for early detection or
prognosis of the disease. It is important here to mention that the
measured methylation values in whole blood are nearly completely
derived from nucleated leucocytes and the effect of circulating
cancer cells or cell free DNA can be excluded. This is because the
expected number of circulating cancer cells is negligible in
comparison to the leukocytes (2 to 8 cells in 4.5 million leucocytes
in a 7.5 ml whole blood) (Albertas please add reference and
rearrange the references). In addition cell free DNA was discarded
because only washed nuclei was used as input for the DNA
extraction.
In summary, this pilot study shows that methylation of whole
blood DNA is associated with pancreatic adenocarcinoma
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pathogenesis. These results indicate that combining multiple gene
methylation profiles could provide greater accuracy than individ-
ual markers in predicting clinical outcomes. We support the
growing evidence that methylation changes arise systematically
and that they can be measured in surrogate tissues, such as
peripheral blood. Therefore, use of peripheral leukocyte DNA
methylation as a surrogate marker of gene silencing and genomic
instability in target tumor tissue must be evaluated in larger
studies.
Materials and Methods
Ethics Statement
This study was approved by the local Bioethics Committee of
the Lithuanian University of Health Sciences (approval number
BE-2-17) and written informed consent was obtained from all
patients.
Gene Selection
For this study, we selected genes of different metabolic
pathways, as certain genes involved in cellular pathways, such as
signal transduction, apoptosis, cell to cell communication, cell
cycles and cytokine signaling, are down-regulated in cancers and
may be considered potential tumor suppressor genes [43].
Therefore, we investigated, p16 [44] and APC [45], as they have
been shown to be methylated at variable frequencies in pancreatic
cancer [46], and apoptotic genes. ACIN1, DAPK1, TNFRSF10C,
BCL2 [34,38,47]; 3OST2 [8], CD44 [48], and RARbeta [49] are
found to be frequently methylated in other human cancers
[34,38,47,50]. For surrogate markers of global methylation, we
selected long interspersed nucleotide elements (LINE-1) and the
most abundant short interspersed nucleotides in the human
genome (Alu).
DNA Samples
This study included 30 pancreatic ductal adenocarcinoma
patients diagnosed at the Department of Hepato-pancreato-biliary
Surgery (Kaunas Medical University Hospital, Lithuania) between
August 2005 and January 2007. All diagnoses were based on
histopathological evidence and patients with adenocarcinoma, the
most common histological type of pancreatic cancer, were
included. The clinical-pathological characteristics of these pan-
creatic ductal adenocarcinoma patients based on the International
Union against Cancer TNM classification are summarized in
Table 1 [51]. Patients had neither undergone chemotherapy or
radiotherapy prior to surgery, nor did they have any other
diagnosed cancer. Blood samples from the patients were taken
directly prior to surgery. The control population consisted of 49
patients with benign diseases (12 with inguinal hernias, eight with
primary ventral hernias and 29 with cholelithiasis). Primary
pancreatic tumors samples were surgically obtained from patients
who underwent resection for pancreatic cancer. Samples were
then divided into two portions. The first portion was fixed in
formalin and was submitted for routine histopathological exam-
ination, while the second portion was immediately snap-frozen
and stored in liquid nitrogen at 280uC until use in further
experiments. Hematoxylin and eosin-stained slide from a frozen
block was reviewed. The tumor cell cellularity was at least 80% in
all samples.
DNA Extraction
Five ml corresponding peripheral venous blood was available
from twenty-six patients with pancreatic ductal adenocarcinoma.
Forty-nine peripheral venous blood samples were obtained from
control population. About 25 mg of pancreatic ductal adenocar-
cinoma tissue was taken for DNA extraction. Genomic DNA was
extracted from tumor tissue and peripheral blood by DNeasyH
Blood and Tissue Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendation.
Bisulfite Modification and PCR
200 ng of genomic DNA was subjected to bisulfite conversion
with the EpiTect Bisulfite kit (Qiagen, Hilden, Germany)
according to the manufacturer’s recommendation. Specific prim-
ers were designed with the assistance of the Methprimer software
on http://www.urogene.org/methprimer (Table S1). PCR was
performed in a 200 ml PCR tube and with a final volume of 30 ml,
containing 6 pmol of each primer, 200 mmol/L of each dNTP,
1.5 U of HOT FIREPol DNA polymerase (Solis BioDyne, Tartu,
Estonia) in buffer B containing 2.5 mmol/L MgCl2 and 2 ml of
bisulfite-treated DNA as template. The initial denaturation (97uC,
15 minutes) was followed by 37 cycles of one minute at 95uC, one
minute at primer specific temperatures (Table S1), one minute at
72uC, and a final extension step at 72uC for 10 minutes.
Site-specific Methylation by SIRPH Analysis
The site-specific methylation measurements at selected CpG
sites were done by the SIRPH method as previously described
[22,23]. The primers used for primer extension are given in Table
S1. We selected one or two CpG sites for every region. The
regions were selected in CpG rich sequences in the promoter
region of the gene of interest (Figure S1). Detailed individual
methylation values can be found in Table S2, while typical SIRPH
chromatograms are shown in figure S2.
Statistical Analysis
Descriptive analyses were performed for age and gender among
cancer cases and controls and for clinical characteristics of the
pancreatic cancer cases. Differences in methylation level values
between cancer cases and controls were analyzed by Mann-
Whitney and Wilcoxon test for related samples. The two-sided x2
test was used to determine associations between the methylation
statuses with various clinical-pathological features. Odds ratios
(ORs) were obtained from the 262 contingency table comparing
binary clinical-pathological variables and methylation level of site
specific CpG. To evaluate the effects of site specific CpG
methylation levels on case-control status, while controlling for
intervariable confounding, logistic regression was performed to
determine odds ratios and their associated 95% confidence
intervals. In this analysis, site-specific CpG relative methylation
level was broken into terciles based on the distribution in controls.
Spearman’s correlation calculation was used to analyze correlation
between all site-specific CpG methylation values. Survival analysis
was performed in accordance with the Kaplan-Meier method,
using the survival time starting from the day of surgery of the
primary tumor to the date of death due to cancer (event) or to the
last day of clinical follow-up (censored). Survival differences among
comparator groups were analyzed by the log-rank test. P,0.05
was considered as significant. Data were analyzed using SPSS
statistical software, version 17.0.0.
Supporting Information
Figure S1 Wild type and bisulfite converted sequences
of studied regions with positioned PCR and SIRPH
primers.
(PDF)
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Figure S2 HPLC chromatograms samples of investigat-
ed CpGs. First peak indicates primer, second peak, ddCTP and
third peak, ddTTP extended oligos. Peak height is automatically
calculated by WAVEMAKERTM software (Transgenomic).
(PDF)
Table S1 Specific primers used for methylation-specific
polymerase chain reaction (Bi) and SIRPH (SN) analysis.
(PDF)
Table S2 Raw data of methylation percentage of
pancreatic ductal adenocarcinoma patients (blood:
patient peripheral blood; tissue: patient tumor tissue)
and control group individuals.
(XLS)
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